Raymond James & Associates Crispr Therapeutics Ag Transaction History

Raymond James & Associates

$150 Billion
Q2 2024

A detailed history of Raymond James & Associates transactions in Crispr Therapeutics Ag stock. As of the latest transaction made, Raymond James & Associates holds 38,433 shares of CRSP stock, worth $1.74 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

38,433

Previous 34,954 9.95%

Holding current value

$1.74 Million

Previous $2.38 Million 12.89%

% of portfolio

0.0%

Previous 0.0%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 19, 2024	BUY	$51.17 - $68.18 $178,020 - $237,198	3,479 Added 9.95%	38,433 $2.08 Million
Q1 2024 Apr 22, 2024	BUY	$60.67 - $89.12 $188,987 - $277,608	3,115 Added 9.78%	34,954 $2.38 Million
Q4 2023 Jan 16, 2024	BUY	$38.62 - $72.18 $124,781 - $233,213	3,231 Added 11.29%	31,839 $1.99 Million
Q3 2023 Oct 24, 2023	SELL	$45.39 - $59.0 $7,217 - $9,381	-159 Reduced 0.55%	28,608 $1.3 Million
Q2 2023 Jul 25, 2023	SELL	$43.47 - $67.77 $1.23 Million - $1.92 Million	-28,365 Reduced 49.65%	28,767 $1.61 Million
Q1 2023 Apr 14, 2023	BUY	$41.0 - $56.12 $562,889 - $770,471	13,729 Added 31.63%	57,132 $2.58 Million
Q4 2022 Feb 08, 2023	BUY	$39.19 - $65.67 $242,037 - $405,577	6,176 Added 16.59%	43,403 $1.76 Million
Q3 2022 Oct 25, 2022	BUY	$61.1 - $83.78 $242,689 - $332,774	3,972 Added 11.94%	37,227 $2.43 Million
Q2 2022 Aug 12, 2022	SELL	$43.23 - $73.83 $792,622 - $1.35 Million	-18,335 Reduced 35.54%	33,255 $2.02 Million
Q1 2022 May 11, 2022	SELL	$53.19 - $79.24 $450,359 - $670,925	-8,467 Reduced 14.1%	51,590 $3.24 Million
Q4 2021 Feb 08, 2022	SELL	$70.09 - $111.29 $1.94 Million - $3.09 Million	-27,729 Reduced 31.59%	60,057 $4.55 Million
Q3 2021 Nov 02, 2021	BUY	$110.2 - $156.64 $934,385 - $1.33 Million	8,479 Added 10.69%	87,786 $9.83 Million
Q2 2021 Aug 11, 2021	BUY	$100.84 - $161.89 $1.7 Million - $2.73 Million	16,859 Added 27.0%	79,307 $12.8 Million
Q1 2021 May 14, 2021	BUY	$110.72 - $210.04 $95,440 - $181,054	862 Added 1.4%	62,448 $7.61 Million
Q4 2020 Feb 12, 2021	BUY	$79.67 - $173.23 $198,537 - $431,689	2,492 Added 4.22%	61,586 $9.43 Million
Q3 2020 Nov 04, 2020	BUY	$78.5 - $100.64 $300,498 - $385,249	3,828 Added 6.93%	59,094 $4.94 Million
Q2 2020 Jul 28, 2020	SELL	$38.5 - $76.05 $26,334 - $52,018	-684 Reduced 1.22%	55,266 $4.06 Million
Q1 2020 Apr 21, 2020	BUY	$33.68 - $62.53 $179,244 - $332,784	5,322 Added 10.51%	55,950 $2.37 Million
Q4 2019 Feb 12, 2020	SELL	$36.68 - $73.13 $170,415 - $339,761	-4,646 Reduced 8.41%	50,628 $3.08 Million
Q3 2019 Nov 07, 2019	BUY	$40.99 - $52.56 $91,981 - $117,944	2,244 Added 4.23%	55,274 $2.27 Million
Q2 2019 Aug 06, 2019	BUY	$35.45 - $48.2 $50,799 - $69,070	1,433 Added 2.78%	53,030 $2.5 Million
Q1 2019 May 06, 2019	BUY	$28.02 - $40.87 $85,180 - $124,244	3,040 Added 6.26%	51,597 $1.84 Million
Q4 2018 Feb 11, 2019	BUY	$22.73 - $42.34 $118,809 - $221,311	5,227 Added 12.06%	48,557 $1.39 Million
Q3 2018 Nov 14, 2018	SELL	$44.35 - $65.71 $1.71 Million - $2.53 Million	-38,476 Reduced 47.03%	43,330 $1.92 Million
Q2 2018 Aug 14, 2018	SELL	$42.62 - $73.59 $22,375 - $38,634	-525 Reduced 0.64%	81,806 $4.81 Million
Q1 2018 May 14, 2018	SELL	$23.52 - $58.17 $11,924 - $29,492	-507 Reduced 0.61%	82,331 $3.76 Million
Q4 2017 Feb 14, 2018	BUY	$16.95 - $23.48 $579,317 - $802,499	34,178 Added 70.24%	82,838 $1.95 Million
Q3 2017 Nov 13, 2017	BUY	$16.75 - $20.66 $479,904 - $591,929	28,651 Added 143.19%	48,660 $870,000
Q2 2017 Aug 14, 2017	BUY	N/A	20,009	20,009 $321,000

Others Institutions Holding CRSP

# of Institutions

523

Shares Held

58M

Call Options Held

1.73M

Put Options Held

1.84M

View Full List

About CRISPR Therapeutics AG

Ticker CRSP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,009,296
Market Cap $3.53B
Description
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....

More about CRSP

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

News

Stay updated on Raymond James & Associates with notifications on news.

Account

Raymond James & Associates Crispr Therapeutics Ag Transaction History